Northern Trust’s Vertex Pharmaceuticals VRTX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$1.15B Sell
2,564,264
-15,193
-0.6% -$7.08M 0.15% 119
2025
Q4
$1.17B Sell
2,579,457
-48,430
-2% -$20.9M 0.15% 114
2025
Q3
$1.03B Sell
2,627,887
-30,694
-1% -$12.8M 0.13% 135
2025
Q2
$1.18B Buy
2,658,581
+39,189
+1% +$18.1M 0.16% 115
2025
Q1
$1.27B Sell
2,619,392
-101,657
-4% -$47.4M 0.19% 104
2024
Q4
$1.1B Buy
2,721,049
+355,057
+15% +$165M 0.16% 115
2024
Q3
$1.1B Sell
2,365,992
-167,912
-7% -$80.7M 0.18% 105
2024
Q2
$1.19B Sell
2,533,904
-44,533
-2% -$19.3M 0.2% 90
2024
Q1
$1.08B Sell
2,578,437
-102,160
-4% -$43.2M 0.19% 102
2023
Q4
$1.09B Sell
2,680,597
-132,966
-5% -$49.1M 0.2% 100
2023
Q3
$978M Buy
2,813,563
+131,539
+5% +$46M 0.19% 102
2023
Q2
$944M Sell
2,682,024
-94,671
-3% -$31.9M 0.18% 107
2023
Q1
$875M Sell
2,776,695
-74,864
-3% -$22.5M 0.17% 114
2022
Q4
$823M Sell
2,851,559
-36,439
-1% -$11.1M 0.17% 117
2022
Q3
$836M Sell
2,887,998
-48,936
-2% -$14.1M 0.19% 102
2022
Q2
$828M Buy
2,936,934
+46,981
+2% +$12.6M 0.18% 109
2022
Q1
$754M Sell
2,889,953
-18,399
-0.6% -$4.37M 0.13% 142
2021
Q4
$639M Sell
2,908,352
-86,138
-3% -$16.7M 0.1% 175
2021
Q3
$543M Buy
2,994,490
+21,674
+0.7% +$4.23M 0.1% 186
2021
Q2
$599M Sell
2,972,816
-5,434
-0.2% -$1.14M 0.11% 169
2021
Q1
$640M Sell
2,978,250
-44,254
-1% -$9.72M 0.12% 155
2020
Q4
$714M Sell
3,022,504
-75,401
-2% -$17.3M 0.14% 137
2020
Q3
$843M Buy
3,097,905
+119,997
+4% +$33.1M 0.18% 100
2020
Q2
$865M Buy
2,977,908
+117,949
+4% +$32M 0.2% 90
2020
Q1
$681M Buy
2,859,959
+18,222
+0.6% +$4.18M 0.2% 105
2019
Q4
$622M Sell
2,841,737
-110,483
-4% -$22.4M 0.14% 143
2019
Q3
$500M Buy
2,952,220
+8,440
+0.3% +$1.49M 0.12% 171
2019
Q2
$540M Buy
2,943,780
+33,009
+1% +$5.77M 0.13% 155
2019
Q1
$535M Buy
2,910,771
+31,978
+1% +$5.91M 0.13% 145
2018
Q4
$477M Buy
2,878,793
+98,585
+4% +$17.1M 0.13% 146
2018
Q3
$536M Sell
2,780,208
-22,732
-0.8% -$4.05M 0.13% 150
2018
Q2
$476M Sell
2,802,940
-6,684
-0.2% -$1.04M 0.12% 166
2018
Q1
$458M Sell
2,809,624
-33,696
-1% -$5.5M 0.12% 174
2017
Q4
$426M Sell
2,843,320
-50,060
-2% -$7.41M 0.11% 186
2017
Q3
$440M Buy
2,893,380
+182,130
+7% +$27.4M 0.11% 174
2017
Q2
$349M Buy
2,711,250
+6,055
+0.2% +$729K 0.1% 207
2017
Q1
$296M Buy
2,705,195
+59,428
+2% +$5.23M 0.09% 238
2016
Q4
$195M Sell
2,645,767
-327,029
-11% -$26.6M 0.06% 314
2016
Q3
$259M Buy
2,972,796
+29,351
+1% +$2.77M 0.08% 248
2016
Q2
$253M Buy
2,943,445
+30,442
+1% +$2.63M 0.08% 250
2016
Q1
$240M Buy
2,913,003
+8,430
+0.3% +$763K 0.08% 250
2015
Q4
$365M Sell
2,904,573
-233,754
-7% -$28.2M 0.12% 163
2015
Q3
$327M Sell
3,138,327
-84,732
-3% -$10.9M 0.11% 184
2015
Q2
$398M Buy
3,223,059
+74,500
+2% +$9.39M 0.12% 167
2015
Q1
$371M Sell
3,148,559
-49,433
-2% -$5.92M 0.11% 186
2014
Q4
$380M Buy
3,197,992
+21,376
+0.7% +$2.41M 0.11% 182
2014
Q3
$357M Buy
3,176,616
+239,143
+8% +$22.8M 0.11% 173
2014
Q2
$278M Sell
2,937,473
-275,784
-9% -$19.3M 0.09% 218
2014
Q1
$227M Buy
3,213,257
+227,875
+8% +$18M 0.07% 271
2013
Q4
$222M Sell
2,985,382
-22,077
-0.7% -$1.54M 0.07% 262
2013
Q3
$228M Buy
3,007,459
+675,024
+29% +$53.7M 0.08% 239
2013
Q2
$187M Buy
+2,332,435
New +$172M 0.07% 283

Other funds holding VRTX

Northern Trust's VRTX Position: Q1 2026 in Review

Northern Trust reduced its Vertex Pharmaceuticals (VRTX) stake by 0.59% in Q1 2026, selling an estimated $7.08M and leaving 2,564,264 shares worth $1.15B. The position accounts for 0.15% of the portfolio, ranked #119.

Northern Trust first reported a position in VRTX in Q2 2013 and has held it in 52 quarters since. The position peaked at $1.27B in Q1 2025. 1,687 funds tracked by Wall St. Rank hold VRTX as of Q1 2026.

  • Northern Trust held 2,564,264 shares of Vertex Pharmaceuticals worth $1.15B as of Q1 2026.
  • Northern Trust sold 15,193 Vertex Pharmaceuticals shares in Q1 2026, an estimated $7.08M.
  • Vertex Pharmaceuticals made up 0.15% of Northern Trust's portfolio in Q1 2026, its #119 holding.
  • Northern Trust first reported a position in Vertex Pharmaceuticals in Q2 2013 and has held it in 52 quarters since.
  • Northern Trust's Vertex Pharmaceuticals position peaked at $1.27B in Q1 2025.
  • 1,687 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2026.

Based on Northern Trust's 13F filing for Q1 2026, filed 14 May 2026.